Kanagasabai, T.; Dunbar, Z.; Ochoa, S.G.; Farris, T.; Dhandayuthapani, S.; Wijeratne, E.M.K.; Gunatilaka, A.A.L.; Shanker, A.
Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP. Cancers 2024, 16, 670.
https://doi.org/10.3390/cancers16030670
AMA Style
Kanagasabai T, Dunbar Z, Ochoa SG, Farris T, Dhandayuthapani S, Wijeratne EMK, Gunatilaka AAL, Shanker A.
Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP. Cancers. 2024; 16(3):670.
https://doi.org/10.3390/cancers16030670
Chicago/Turabian Style
Kanagasabai, Thanigaivelan, Zerick Dunbar, Salvador González Ochoa, Tonie Farris, Sivanesan Dhandayuthapani, E. M. Kithsiri Wijeratne, A. A. Leslie Gunatilaka, and Anil Shanker.
2024. "Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP" Cancers 16, no. 3: 670.
https://doi.org/10.3390/cancers16030670
APA Style
Kanagasabai, T., Dunbar, Z., Ochoa, S. G., Farris, T., Dhandayuthapani, S., Wijeratne, E. M. K., Gunatilaka, A. A. L., & Shanker, A.
(2024). Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP. Cancers, 16(3), 670.
https://doi.org/10.3390/cancers16030670